Marko Georgiev/Getty Images News
- Merck (NYSE:MRK) said that its experimental KRAS G12C inhibitor MK-1084 showed promising antitumor activity in a phase 1 study of patients with colorectal cancer ("CRC") and non-small cell lung cancer (NSCLC).
- In those with advanced KRAS G12C-mutated CRC and NSCLC, a